1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

GlobalData anticipates that Pfizer’s PCSK9 mAb, bococizumab (PF-04950615), will be the third-to-market PCSK9 inhibitor behind Amgen’s evolocumab and Sanofi and Regeneron’s alirocumab, which GlobalData expects are first and second in line for US regulatory approval, respectively. Similar to these other PCSK9 inhibitors, bococizumab is heading into Phase III studies with positive Phase II dosing and LDL-C lowering results. A novel set of LDL-C drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce levels of LDL-C by enhancing the liver’s ability to filter LDL-C particles from the circulation.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22
4 Disease Management 24
4.1 Treatment Overview 24
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor Assessment 31
6 Unmet Need and Opportunity 36
6.1 Overview 36
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 37
6.2.1 Unmet Need 37
6.2.2 Gap Analysis 38
6.2.3 Opportunity 38
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 43
6.4.3 Opportunity 45
6.5 Antidotes for New Oral Anticoagulants (NOACs) 45
6.5.1 Unmet Need 45
6.5.2 Gap Analysis 46
6.5.3 Opportunity 46
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 47
6.6.1 Unmet Need 47
6.6.2 Gap Analysis 48
6.6.3 Opportunity 48
7 Pipeline Assessment 50
7.1 Overview 50
7.2 Clinical Trials by Phase and Trial Status 52
7.3 Promising Drugs in Clinical Development 54
8 Bococizumab (PF-04950615) 59
8.1 Overview 59
8.2 Efficacy 61
8.3 Safety 61
8.4 Dosing and Formulation 61
8.5 Potential Clinical Positioning 62
8.6 Potential Commercial Positioning 62
8.7 Pricing and Reimbursement 62
8.8 SWOT Analysis 63
8.9 Forecast 63
9 Appendix 65
9.1 Bibliography 65
9.2 Abbreviations 71
9.3 Methodology 75
9.4 Forecasting Methodology 75
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 75
9.4.2 Diagnosed Acute Coronary Syndrome Patients 76
9.4.3 Percent Drug-Treated Patients 77
9.4.4 General Pricing Assumptions 77
9.4.5 Generic Erosion 79
9.4.6 Pricing of Pipeline Agents 79
9.5 Physicians and Specialists Included in this Study 79
9.6 About the Authors 82
9.6.1 Author 82
9.6.2 Reviewer 82
9.6.3 Global Head of Healthcare 83
9.7 About GlobalData 84
9.8 Disclaimer 84

1.1 List of Tables

Table 1: Antiplatelet Agents that Inhibit Platelet Activation 18
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade 18
Table 3: Symptoms of Acute Coronary Syndrome 23
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 27
Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014 29
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014 35
Table 7: Unmet Need and Opportunity in Acute Coronary Syndrome 37
Table 8: Acute Coronary Syndrome - Clinical Trials by Phase and Status, 2014 53
Table 9: Acute Coronary Syndrome - Late-Stage Pipeline, 2014 56
Table 10: Comparison of Therapeutic Classes in Development for ACS, 2014 57
Table 11: Product Profile - Bococizumab (PF-04950615) 60
Table 12: Bococizumab (PF-04950615) SWOT Analysis, 2014 63
Table 13: Global Sales Forecasts ($m) for Bococizumab, 2013-2023 64
Table 14: Price Sources and Calculations, by Country 78
Table 15: Physicians Surveyed, By Country 81

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 16
Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome 17
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 19
Figure 4: Electrocardiography in the Diagnosis of ACS 20
Figure 5: Acute Coronary Syndrome Therapeutics - Clinical Trials by Phase in the 7MM, 2014 54
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents for ACS, 2013-2023 58

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.